2019
Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors.
Jamwal S, Mittal A, Kumar P, Alhayani DM, Al-Aboudi A. Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors. Current Pharmaceutical Design 2019, 25: 2892-2905. PMID: 31333104, DOI: 10.2174/1381612825666190716112319.Peer-Reviewed Original ResearchConceptsCentral nervous systemNervous systemFast excitatory postsynaptic currentsCerebral blood flowExcitatory postsynaptic currentsPeripheral nervous systemAntagonists of A1Pharmacology of adenosineA3 adenosine receptorAutonomic gangliaPostsynaptic currentsReceptor agonistMetabolic dysfunctionBlood flowNeuronal activityOcular diseasesSynaptic terminalsTherapeutic strategiesAdenosine receptorsTherapeutic potentialChemical transmissionATP actsExtracellular concentrationReceptors vizNerve signals
2017
Animal Models of Epilepsy
Koshal P, Jamwal S, Akula K, Bansal P. Animal Models of Epilepsy. 2017, 59-78. DOI: 10.1007/978-981-10-5981-0_5.Peer-Reviewed Original ResearchCentral nervous systemAntiepileptic drugsEpileptic seizuresPrinciple inhibitory neurotransmitterDevelopment of epilepsyLong-term outcomesType of epilepsyExcessive electrical dischargesGABAergic axon terminalsTreatment of epilepsyCommon neurological disorderPopulations of neuronsAmino butyric acidFrequent seizuresGABAB receptorsSecondary complicationsInhibitory neurotransmitterGABAA receptorsMotor disordersAxon terminalsEpileptic patientsHealthcare costsAnimal modelsNervous systemNeonatal stage